Patent SG-11201902465T-A (SG)
Title: Inhibitors of mtor-deptor interactions and methods of use thereof
Inventor: LICHTENSTEIN ALAN
IPC: A61P35/00
Filed: 2017-11-06
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Al 11111111 0 1111111111111111 011001 0 0111111111111001H1111111011111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/085753 Al 11 May 2018 (11.05.2018) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, CO7C 251/84 (2006.01) A61K 31/15 (2006.01) KM, ML, MR, NE, SN, TD, TG). CO7C 281/04 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: Declarations under Rule 4.17: PCT/US2017/060116 — of inventorship (Rule 4.17(iv)) (22) International Filing Date: Published: 06 November 2017 (06.11.2017) — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (25) Filing Language: English claims and to be republished in the event of receipt of (26) Publication Language: English amendments (Rule 48.2(h)) (30) Priority Data: 62/418,362 07 November 2016 (07.11.2016) US (71) Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200 (US). THE UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS [US/US]; Office of the General Counsel, Washington, DC 20420 (US). Inventors: LICHTENSTEIN, Alan; 5002 Valjean Ave., Encino, CA 91436 (US). JUNG, Michael E.; 2335 Man- = (72) ning Avenue, Los Angeles, CA 90064 (US). GERA, Joseph F.; 42349 Sunnyslope Drive, Lancaster, CA 93536 =_ (US). LEE, Jihye; 2440 S. Barrington Ave. #307, Los An- geles, CA 90064 (US). SHI, Yijiang; 1334 19th Street, San- - to Monica, CA 90404 (US). Agent: HALSTEAD, David P. et al.; Foley Hoag LLP, 155 (74) — Seaport Boulevard, Boston, MA 02210-2600 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (81) = = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, — DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = — SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every (84) = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — 1-1 M 4.) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1 1 i n MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, IN 1 1 i n 00 © CO (54) Title: INHIBITORS OF MTOR-DEPTOR INTERACTIONS AND METHODS OF USE THEREOF 1-1 0 (57) : Provided herein are substituted hydrazone compounds useful as inhibitors of DEPTOR. The invention further provides ei pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted hydrazone C: compounds.